Results
1 -
10 of
49A difference between the rat and mouse in the pharmacokinetic interaction of 5,6-dimethylxanthenone-4-acetic acid with thalidomide, Cancer Chemotherapy and Pharmacology Using Metabolomics to Monitor Anticancer Drugs, Oncogenes Meet Metabolism ASA404 (DMXAA): New Concepts in Tumour Vascular Targeting Therapy, Vascular Disruptive Agents for the Treatment of Cancer Lessons from Animal Imaging in Preclinical Models, Vascular Disruptive Agents for the Treatment of Cancer Vascular Disruptive Agents in Combination with Radiotherapy, Vascular Disruptive Agents for the Treatment of Cancer Combination Therapy with Chemotherapy and VDAs, Vascular Disruptive Agents for the Treatment of Cancer Identification and Development of Vascular Disrupting Agents: Natural Products That Interfere with Tumor Growth, Natural Products and Cancer Drug Discovery The Use of Animal Models in the Assessment of Tumour Vascular Disrupting Agents (VDAs), Vascular Disruptive Agents for the Treatment of Cancer Targeting Tumour Vascularization from Bench to Bedside: Suggestions for Combination with Hyperthermia, Cancer Microenvironment and Therapeutic Implications MRI to Assess Vascular Disruptive Agents, Vascular Disruptive Agents for the Treatment of Cancer